LBX Pharmacy Chain JSC (SHSE:603883) EBIT: ¥965 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603883 LBX Pharmacy Chain JSC SHSE:603883
82 GF Score
Price ¥13.58
GF Value ¥18.13
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is LBX Pharmacy Chain JSC EBIT?

LBX Pharmacy Chain JSC SHSE:603883 -0.88% 82 EBIT is ¥965 Mil as of Jun. 2026. GuruFocus rates SHSE:603883 with a GF Score™ of 82/100 and a GF Value™ of ¥18.13 (Modestly Undervalued). The stock has 4 warning signs investors should review.

LBX Pharmacy Chain JSC's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was ¥342 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was ¥965 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. LBX Pharmacy Chain JSC's annualized ROC % for the quarter that ended in Jun. 2026 was 7.66%. LBX Pharmacy Chain JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 41.58%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. LBX Pharmacy Chain JSC's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 7.68%.

LBX Pharmacy Chain JSC  (SHSE:603883) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

LBX Pharmacy Chain JSC's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=1375.756 * ( 1 - 28.67% )/( (12974.336 + 12635.685)/ 2 )
=981.3267548/12805.0105
=7.66 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=19907.237 - 7964.563 - ( 2668.574 - max(0, 10049.651 - 9017.989+2668.574))
=12974.336

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=19067.262 - 7329.255 - ( 2317.518 - max(0, 9206.416 - 8308.738+2317.518))
=12635.685

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

LBX Pharmacy Chain JSC's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1366.54/( ( (3334.236 + max(-2089.974, 0)) + (3238.151 + max(-1837.305, 0)) )/ 2 )
=1366.54/( ( 3334.236 + 3238.151 )/ 2 )
=1366.54/3286.1935
=41.58 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1988.46 + 3633.61 + 461.967) - (7964.563 + 0 + 209.448)
=-2089.974

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1754.743 + 3474.919 + 481.794) - (7329.255 + 0 + 219.506)
=-1837.305

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

LBX Pharmacy Chain JSC's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=965.416/12563.590
=7.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LBX Pharmacy Chain JSC EBIT Related Terms

LBX Pharmacy Chain JSC EBIT Historical Data

* Premium members only.

The historical data trend for LBX Pharmacy Chain JSC's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LBX Pharmacy Chain JSC EBIT Chart

LBX Pharmacy Chain JSC Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,154.12 1,439.75 1,593.44 1,094.22 886.44

LBX Pharmacy Chain JSC Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 275.45 202.17 7.84 413.77 341.64

LBX Pharmacy Chain JSC EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, LBX Pharmacy Chain JSC's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LBX Pharmacy Chain JSC EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, LBX Pharmacy Chain JSC's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where LBX Pharmacy Chain JSC's EV-to-EBIT falls into.


SHSE:603883
82GF Score
LBX Pharmacy Chain JSC SHSE:603883
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LBX Pharmacy Chain JSC EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥965 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥965 Mil mean?
LBX Pharmacy Chain JSC (SHSE:603883) has a EBIT of ¥965 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on LBX Pharmacy Chain JSC.
Is LBX Pharmacy Chain JSC's EBIT too high?
LBX Pharmacy Chain JSC's current EBIT is ¥965 Mil. Overall, LBX Pharmacy Chain JSC has a GF Score™ of 82/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does LBX Pharmacy Chain JSC's EBIT compare to competitors?
LBX Pharmacy Chain JSC's EBIT of ¥965 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on LBX Pharmacy Chain JSC. LBX Pharmacy Chain JSC's current EBIT is ¥965 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LBX Pharmacy Chain JSC stock overvalued right now?
Based on GuruFocus' analysis, LBX Pharmacy Chain JSC (SHSE:603883) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.13, compared to a current price of ¥13.58 — trading 25.1% below its estimated fair value. The current EBIT is ¥965 Mil. LBX Pharmacy Chain JSC's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For LBX Pharmacy Chain JSC (SHSE:603883), the current EBIT is ¥965 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LBX Pharmacy Chain JSC (SHSE:603883) Overvalued in 2026?

Based on GuruFocus' analysis, LBX Pharmacy Chain JSC stock appears to be undervalued. The current stock price of ¥13.58 is trading 25.1% below its estimated GF Value™ of ¥18.13. GuruFocus considers LBX Pharmacy Chain JSC to be Modestly Undervalued.

Key valuation signals for SHSE:603883:

  • EBIT: ¥965 Mil
  • GF Value™: ¥18.13 vs. price of ¥13.58 (25.1% below fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603883 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LBX Pharmacy Chain JSC Business Description

Address No. 288, Xiangya Road, Kaifu District, Hunan, Changsha, CHN, 410005
LBX Pharmacy Chain JSC is a China-based company engages in the sale of medicine and health products. The company is engaged in retailing drugs and other related products, including Chinese and Western medicine, prepared slices of Chinese crude drugs, health equipment, healthy food, and personal care products and life care products. The company is also involved in the wholesale and manufacture of drugs.
82GF Score

Get the complete analysis for SHSE:603883

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥13.58
Price
¥18.13
GF Value